Table 1 Enrolled patients’ characteristics in the overall cohort.
Immunotherapy (N = 99) | Immunotherapy + radiotherapy (N = 39) | p.value | |
|---|---|---|---|
Sex | 0.779 | ||
Female | 13 (13.1%) | 4 (10.3%) | |
Male | 86 (86.9%) | 35 (89.7%) | |
Age | 61.6 ± 7.43 | 61.1 ± 8.70 | 0.771 |
Smoking | 1.000 | ||
No | 25 (25.3%) | 10 (25.6%) | |
Yes | 74 (74.7%) | 29 (74.4%) | |
Drinking | 0.641 | ||
No | 60 (60.6%) | 26 (66.7%) | |
Yes | 39 (39.4%) | 13 (33.3%) | |
Antecedent chronic illnesses | 1.000 | ||
No | 74 (74.7%) | 29 (74.4%) | |
Yes | 25 (25.3%) | 10 (25.6%) | |
Histology | 0.058 | ||
Adenocarcinoma | 58 (58.6%) | 29 (74.4%) | |
Others | 10 (10.1%) | 0 (0.00%) | |
Squamous cell | 31 (31.3%) | 10 (25.6%) | |
T stage | 0.188 | ||
T1 | 12 (12.1%) | 5 (12.8%) | |
T2 | 19 (19.2%) | 14 (35.9%) | |
T3 | 19 (19.2%) | 3 (7.69%) | |
T4 | 45 (45.5%) | 15 (38.5%) | |
N stage | 0.978 | ||
N0 | 13 (13.1%) | 6 (15.4%) | |
N1 | 7 (7.07%) | 2 (5.13%) | |
N2 | 24 (24.2%) | 8 (20.5%) | |
N3 | 52 (52.5%) | 22 (56.4%) | |
PD-L1 expression | 0.869 | ||
1–49% | 26 (26.3%) | 10 (25.6%) | |
< 1% | 12 (12.1%) | 5 (12.8%) | |
≥ 50% | 13 (13.1%) | 3 (7.69%) | |
ECOG | 1.000 | ||
< 2 | 95 (96.0%) | 37 (94.9%) | |
≥ 2 | 4 (4.04%) | 2 (5.13%) | |
The number of BMs | 0.431 | ||
Multiple | 76 (76.8%) | 33 (84.6%) | |
Single | 23 (23.2%) | 6 (15.4%) | |
The number of EMs | 0.742 | ||
No | 51 (51.5%) | 22 (56.4%) | |
Yes | 48 (48.5%) | 17 (43.6%) | |
Bone | 0.454 | ||
Yes | 39 (39.4%) | 12 (30.8%) | |
Liver | 0.292 | ||
Yes | 6 (6.06%) | 5 (12.8%) | |
Adrenal | 0.781 | ||
Yes | 19 (19.2%) | 6 (15.4%) | |
Types of ICIs | 1.000 | ||
PD-1 | 95 (96.0%) | 38 (97.4%) | |
PD-L1 | 4 (4.04%) | 1 (2.56%) | |
Chemotherapy | 0.321 | ||
No | 5 (5.05%) | 0 (0.00%) | |
Yes | 94 (94.9%) | 39 (100%) | |
Targeting angiogenesis | 1.000 | ||
No | 64 (64.6%) | 25 (64.1%) | |
Yes | 35 (35.4%) | 14 (35.9%) | |
Thoracic surgery | 0.193 | ||
No | 98 (99.0%) | 37 (94.9%) | |
Yes | 1 (1.01%) | 2 (5.13%) | |
Brain surgery | 0.711 | ||
No | 82 (82.8%) | 34 (87.2%) | |
Yes | 17 (17.2%) | 5 (12.8%) | |
Corticosteroid or mannitol | 0.031* | ||
No | 55 (55.6%) | 13 (33.3%) | |
Yes | 44 (44.4%) | 26 (66.7%) | |
Thoracic radiotherapy | 0.053 | ||
No | 97 (98.0%) | 35 (89.7%) | |
Yes | 2 (2.02%) | 4 (10.3%) | |
Symptomatic BMs | 0.332 | ||
No | 59 (59.6%) | 19 (48.7%) | |
Yes | 40 (40.4%) | 20 (51.3%) | |
SII | 1243 ± 1244 | 1183 ± 1019 | 0.772 |
NLR | 4.14 ± 2.41 | 4.72 ± 3.47 | 0.344 |
PLR | 203 ± 127 | 202 ± 131 | 0.968 |
LMR | 2.81 ± 1.58 | 2.62 ± 1.22 | 0.468 |
